If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 21 - 30 of 299
A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
Objective
Phase 1-2 DISC-0974 in Myelofibrosis and Anemia
Protocol No
DISC-0974-102
Categories
A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin Versus No HIPEC At the Time of Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian
Objective
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal & FT
Protocol No
GOG-3068-HOTT-HIPEC
Categories
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer
Objective
To assess the safety, tolerability, and PK and to determine RP2DR of REGN4336
separately as monotherapy or in combination with cemiplimab.
separately as monotherapy or in combination with cemiplimab.
Protocol No
REGENERON-R4336-ONC-20104
A Phase 1b/2, Multicenter, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-Line Induction or Maintenance, in Subjects with Extensive-Stage
Objective
A Phase 1b 2 Study of I-DXd, ADC, in Combination in Patients with ES-SCLC
Protocol No
DAIICHI-SANKYO-DS7300-189
Categories
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)
Objective
Felzartamab for the Treatment of Late Antibody-Mediated Rejection in Kidney Transplant Recipients
Protocol No
SURG-BIOGEN-TRANSCEND
Categories
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients A
Objective
Testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia
Protocol No
SWOG-MM1YA-S01
Categories
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE
Objective
Oral Upadacitinib in Adults with Mild to Moderate SLE
Protocol No
RHEU-ABBVIE-SELECT-SLE
Categories
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema: The CONVERT II Trial
Objective
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema
Protocol No
PULM-PULMONX-CONVERT-II
Categories
A Multicenter Randomized Controlled Trial to Establish the Impact of MeMed BV® on Management of Patients with Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) (JUPITER TRIAL)
Objective
Management of LRTI in the ED and UCC - JUPITER
Protocol No
EM-MEMED-JUPITER
Categories
Symptom Monitoring Using Patient-Reported Outcomes To Optimize Medication Use
Objective
SyMPTOM Study
Protocol No
IIT-FLYNN-SYMPTOM
Categories